PRINCETON, NJ – Oct. 6, 2016 – Certara announces that Kelley Kendle, president of Synchrogenix, its medical and regulatory writing consultancy, has been named a Delaware Business Times (DBT) 40 honoree. This is an annual listing of Delaware’s influential achievers and innovators under the age of 40.
Metritis is a frequent problem in postpartum dairy cows. Intrauterine therapy with the antimicrobial oxytetracycline (OTC) is often used, although this therapy has not been shown to be superior to…
Editor’s note: Jason Rock served as Project Lead for the HL7 RCRIM Expert Working Group that developed the Regulated Product Submissions (RPS) standard. This post is the third in a…
D360 Express is an out-of-the-box integrated solution specifically designed for discovery scientists at smaller pharmaceutical research organizations. It provides access, integration, analysis and visualization of scientific data from multiple data sources. D360 Express gets you up and running quickly and affordably.
Foreign sponsors of drug applications who want to conduct business in the United States need an authorized U.S. Agent to interact with the FDA on their behalf. Expectations for the…
全球有 7,000 种罕见疾病困扰着 3.5 亿患者，但其中仅 300 种疾病拥有获批疗法。这一缺口影响了 95% 的罕见病患者群体，意味着巨大的未满足医疗需求。建模与模拟方法不仅是罕见病药物开发的理想工具，更获得监管机构的大力倡导。
The prevalence of cigarette smoking remains high globally despite abundant evidence showing that it isn’t good for your health. But, did you know that smoking can affect the metabolism of…
Get up-to-speed on Study Data Standardization Plan (SDSP) for FDA submissions. Read the blog post to find out more…
Discovery drug research requires understanding complex biological, chemical, logistical and computational data from a wide variety of data sources. Certara’s D360 platform was specifically designed to meet the discovery researcher’s workflow needs.
© 2025 Certara. 保留所有权力。 | 隐私政策
